Expression of thymidylate synthase and orotate phosphoribosyltransferase in thymic carcinoma

Yokota,Keisuke; Sasaki,Hidefumi; Okuda,Katsuhiro; Shitara,Masayuki; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/etm.2012.641

Expression of thymidylate synthase and orotate phosphoribosyltransferase in thymic carcinoma

Authors:
- Keisuke Yokota
- Hidefumi Sasaki
- Katsuhiro Okuda
- Masayuki Shitara
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Published online on: July 19, 2012 https://doi.org/10.3892/etm.2012.641
Pages: 589-593

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymic carcinoma is a rare thymic epithelial tumor in which chemotherapy for advanced disease has not yet been established. Thymidylate synthase (TS) and orotate phosphoribosyltransferase (OPRT) protein expression levels in thymic carcinoma were evaluated as possible indicators of the anticancer activity of 5-fluorouracil (5-FU) drugs using immunohistochemistry (IHC). A total of 24 samples of thymic carcinoma were used in the present study. The tumor sections were immunohistochemically stained for TS and OPRT. As a comparison with thymic carcinoma, we also assessed the TS and OPRT protein expression levels in 55 lung cancer samples. The TS expression was positive in 12 of 24 thymic carcinoma samples (50%) and OPRT expression was positive in 10 (42%). The association between TS and OPRT expression and Masaoka stages of thymic carcinoma was analyzed. The TS and OPRT expressions in stage IV were significantly higher compared to that in stages I, II or III. We also compared the TS and OPRT expression levels between thymic carcinoma and lung cancer (33 adenocarcinomas and 22 squamous cell carcinomas). TS expression in thymic carcinoma was significantly lower compared with lung squamous cell carcinoma. OPRT expression in thymic carcinoma was significantly higher compared to lung adenocarcinoma. The combination of a relatively low expression of TS and high expression of OPRT suggests an improved antitumor effect of 5-FU drugs in thymic carcinoma compared to in lung carcinoma.

View Figures

View References

1	Shimosato Y, Kameya T, Nagai K and Suemasu K: Squamous cell carcinoma of the thymus. An analysis of eight cases. Am J Surg Pathol. 1:109–121. 1977. View Article : Google Scholar : PubMed/NCBI
2	Yano M, Sasaki H, Yokoyama T, et al: Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol. 3:265–269. 2008. View Article : Google Scholar : PubMed/NCBI
3	Yano M, Sasaki H, Yokoyama T, et al: Thymic carcinoma with dissemination: a retrospective analysis of ten patients. Gen Thorac Cardiovasc Surg. 56:335–339. 2008. View Article : Google Scholar : PubMed/NCBI
4	Loehrer PJ Sr, Jiroutek M, Aisner S, et al: Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer. 91:2010–2015. 2001. View Article : Google Scholar : PubMed/NCBI
5	Koisumi T, Takabayashi Y, Yamagashi S, et al: Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol. 25:266–268. 2002. View Article : Google Scholar : PubMed/NCBI
6	Yoh K, Goto K, Ishii G, et al: Weekly chemotherapy with ciaplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer. 98:926–931. 2003. View Article : Google Scholar : PubMed/NCBI
7	Oguri T, Achiwa H, Kato D, et al: Efficacy of docetaxel as a second-line chemotherapy for thymic carcinoma. Chemotherapy. 50:279–282. 2004. View Article : Google Scholar : PubMed/NCBI
8	Komatsu Y, Koizumi T, Tanabe T, et al: Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma – three cases. Anticancer Res. 26:4851–4855. 2006.PubMed/NCBI
9	Loehrer P, Yiannoutsos C and Dropcho S: A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. Am Soc Clin Oncol. 24:70792006.
10	Magois E, Guigay J, Blancard PS, et al: Multimodal treatment of thymic carcinoma: report of nine cases. Lung Cancer. 59:126–132. 2008. View Article : Google Scholar : PubMed/NCBI
11	Tagawa T, Ohta M, Kuwata T, et al: S-1 plus cisplatin chemotherapy with concurrent radiation for thymicbasaloid carcinoma. J Thorac Oncol. 5:572–573. 2010. View Article : Google Scholar : PubMed/NCBI
12	Okuma Y, Shimokawa T, Takagi Y, et al: S-1 is an active anticancer agent for advanced thymic carcinoma. Lung Cancer. 70:357–363. 2010. View Article : Google Scholar : PubMed/NCBI
13	Koizumi T, Agatsuma T, Komatsu Y and Kubo K: Successful S-1 monotherapy for chemorefractory thymic carcinoma. Anticancer Res. 31:299–301. 2011.PubMed/NCBI
14	Totani Y, Saito Y, Hayashi M, et al: A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 64:1181–1185. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels of for thymidylate synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar
16	Ishihama H, Chida M, Araki O, et al: Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. Jpn J Clin Oncol. 39:33–36. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zheng Z, Li X, Schell MJ, et al: Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 112:2765–2773. 2008. View Article : Google Scholar : PubMed/NCBI
18	Sasaki H, Fukai I, Kiriyama M, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in thymoma. Surg Today. 33:83–88. 2003. View Article : Google Scholar : PubMed/NCBI
19	Johnston PG, Lenz HJ and Leichman CG: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 55:1407–1412. 1995.PubMed/NCBI
20	Lenz H, Leichman CG, Danenberg KD, et al: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol. 14:176–182. 1995.PubMed/NCBI
21	Obara S, Yamamoto K, Hosogai N and Yoshimura Y: Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma. Oral Oncol. 41:276–282. 2005. View Article : Google Scholar : PubMed/NCBI
22	Ogiuchi Y, Maruoka Y, Ando T, et al: Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem. 41:39–46. 2008. View Article : Google Scholar
23	Chattopadhyay S, Moran RG and Goldman ID: Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 6:404–417. 2007. View Article : Google Scholar : PubMed/NCBI